Skills & Prompts
Run Amass in any assistant
Paste-ready prompts and packaged skills that turn Amass into finished analyst work in Claude, Codex, Copilot, or any MCP-compatible assistant. Each carries a real, validated answer and downloadable take-home files, and needs no build or deploy.
13 items

Landscape Monitor
Name a field; get it mapped across trials, papers, patents, drugs, genes and approvals into a landscape page with charts, a workbook and a one-page briefing, every record screened with its reason. Ask for an update later to see what is new and what changed.
Open showcase| Short name | Source id | Registry | Copy of |
|---|---|---|---|
| Acute, 50/75 mg vs placebo | NCT04072354 | ClinicalTrials.gov | |
| ↳ EUCTR2019-000470-36-BG | EU CTR | NCT04072354 | |
| Acute, 75/100 mg vs placebo | NCT04092686 | ClinicalTrials.gov |
Watchlist Monitor
Name the trials, papers, approvals or drugs you need to follow; get one Excel board that re-reads them through Amass at every check and tells you exactly what changed: status, dates, enrollment, results posted, label revisions, retractions, new links.
| kinase | kinase_family_chembl_leaf | small_molecule_tractability | protac_tractability |
|---|---|---|---|
| PLK1 | Other protein kinase PLK family | Advanced Clinical | predictive-only |
| WEE1 | Other protein kinase WEE family | Advanced Clinical | predictive-only |
| CDK1 | CMGC protein kinase CDK5 subfamily | Advanced Clinical | predictive-only |
Target prioritization matrix
A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.
| record_type | title | id | source |
|---|---|---|---|
| paper | Mechanisms of Resistance to KRASG12C Inhibitors | PMID:33466360 | Cancers (JuFo 2) |
| paper | Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges | PMID:34607583 | Molecular Cancer (JuFo 3) |
| paper | KRAS G12C Mutations in NSCLC: From Target to Resistance | PMID:34064232 | Cancers (JuFo 2) |
Biomedical Evidence Scout
Name a drug, target, mechanism, or indication; get a landscape briefing that maps the published literature AND the clinical pipeline together — every paper and trial carrying a real Amass ID, PMID, or NCT you can check.
| rank | title | journal | publicationDate |
|---|---|---|---|
| 1 | Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | The New England journal of medicine | 2022-02-10 |
| 2 | Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial | JAMA network open | 2023-04-03 |
| 3 | Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial | medRxiv (preprint) | 2022-09-21 |
Trial evidence trace
Paste one clinical-trial ID; get the exact published papers that describe it — pulled from Amass's publication↔trial graph, with trust metadata and abstract-grounded relevance notes.
1. Pivotal Phase-3 program
AMASS EVIDENCE BRIEF
Tirzepatide evidence brief
Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.
EXPLORER-HCM - NCT03470545 (16 describing papers)
Submission Evidence Assembler - mavacamten (Camzyos)
Submission evidence assembler
Name one drug asset; get a citation-auditable, Module-2.5-style evidence narrative — every pivotal Phase-3 trial, its describing papers, and a canonical Amass-ID audit trail — assembled from Amass's publication↔trial graph with trust metadata on every cited paper.

Resmetirom evidence snapshot
Name a drug asset; get a one-page PDF evidence snapshot — regulatory status, pivotal trials, grounded efficacy figures and the trial↔paper link — every number verbatim from Amass.
| PMID | AMBC | title | journal |
|---|---|---|---|
| 25037936 | AMBC_LgGUu4qEoXy99ZBBdZt6kLYpaq9 | Modeling and research on research | Clinical chemistry |
| 29534060 | AMBC_VRlhiy7cmm9d5q13WjyMr2UA9I0 | Meta-research: Why research on research matters | PLoS biology |
| 15878467 | AMBC_Mk6C6o15EdZyjpf9Pl1vmAoKBoz | Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials | Journal of clinical epidemiology |
ORCID record self-verify
Paste your own ORCID; get the publication record Amass indexes under that verified identity, screened in one pass for retractions, below-peer-review journals, and trial linkage — a clean integrity self-audit before a grant, tenure, or promotion submission.
| KOL paper-trial triangulator — Mikhail Kosiborod · query "cardiometabolic heart failure" | |||
|---|---|---|---|
| Top-10 by relevance (sample, not the full oeuvre). Source: Amass BiomedCore authorNames seed + per-paper referencesTrialCore edge. 6/10 trial-linked, 4/10 (meta-analyses/reviews) none. 0 retracted. | |||
| paper_PMID | paper_AMBC | title | journal |
| 35228754 | AMBC_7BiZMrt83VZHgdVwEesrmHqQ0MB | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (EMPULSE) | Nature medicine |
KOL paper-trial triangulator
Name a KOL plus a context query; get their top-10 most relevant papers, each triangulated to the exact clinical trial it reports — pulled from Amass's publication↔trial graph, with trust metadata and a downloadable engagement-dossier workbook.
| NCT | acronym | drug (interventionNames) | sponsor |
|---|---|---|---|
| NCT01051219 | FELINE | Losartan | Newcastle-upon-Tyne Hospitals NHS Trust |
| NCT03053050 | STELLAR-3 | SEL; Placebo to match SEL 6 mg; Placebo to match SEL 18 mg | Gilead Sciences |
| NCT03900429 | MAESTRO-NASH | MGL-3196; Placebo; Liver Biopsy | Madrigal Pharmaceuticals, Inc. |
Indication pipeline landscape
Name one indication; get its current Phase-3 drug pipeline mapped across every sponsor — each program tagged novel-agent vs repurposed-generic and overlaid with a cross-core publication-evidence maturity count — in one downloadable Excel matrix.
Lecanemab is FDA-approved for early Alzheimer's disease. In its 18-month phase-3 trial it delayed cognitive and functional decline by ≈5 months versus…
Trust-filtered grounded answer
Ask a clinical question; get an answer where every sentence is pinned to a high-quality, non-retracted paper — and anything the evidence can't support is refused, not fabricated.
| rank | title | journal | year |
|---|---|---|---|
| 1 | A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine | Journal of translational medicine | 2021 |
| 2 | Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis | Journal of translational medicine | 2017 |
| 3 | Glioma gene therapy using induced pluripotent stem cell derived neural stem cells | Molecular pharmaceutics | 2011 |
Retraction hotspot scan
Name a research topic; get a checkable, downloadable list of the retracted papers Amass indexes on it — ranked by citation reach, with strict no-reason guardrails.
Get started
Bring cited evidence into your assistant.
Connect the Amass MCP once, then run any of these workflows on your own targets, with every answer traceable to source.
- Data
- No training on your data
- Hosting
- EU-hosted, enterprise
- Isolation
- Tenant-isolated by architecture
- Certification
- ISO 27001, SOC 2, NIS2: in motion